#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives
whatshot 200 snips
Apr 20, 2026
A deep dive into why prostate cancer screening guidelines may be missing dangerous disease. The conversation explores PSA trends, MRI, PSA density, and safer biopsy methods reshaping early detection. It also looks at active surveillance, flawed anti-screening evidence, and how drugs like finasteride can hide warning signs.
46:21
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
How Old PSA Screening Created Real Harm
Early PSA screening created harm because elevated PSA often triggered transrectal biopsy and immediate treatment, even for cancers unlikely to spread.
Peter Attia says biopsies caused 5 to 7% infection rates and treatment often brought erectile dysfunction, incontinence, bowel problems, and psychological burden.
insights INSIGHT
What Happened After Screening Pulled Back
Peter Attia says pulling back on PSA screening predictably shifted diagnosis from curable early disease toward metastatic disease.
He cites U.S. data showing stage 3 rising 3.3% yearly and stage 4 rising 6% yearly while stage 2 detection declines.
insights INSIGHT
Why PSA Velocity Beats A Single PSA Number
Peter Attia says PSA becomes useful when tracked as a personal trend rather than judged as a one-off number.
He highlights PSA velocity red flags above about 0.35 ng/mL yearly below PSA 4, then pairs that with MRI-based PSA density.
Get the Snipd Podcast app to discover more snips from this episode
In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.
We discuss:
The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];
PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];
The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];
How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];
Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];
Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];
Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];
Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];
How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];
The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and
The Peter Attia Drive